1. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005;365:331-340.
[CROSSREF] [PUBMED]
2. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010;21:1819-1834.
[CROSSREF] [PUBMED]
3. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006;17:17-25.
[CROSSREF] [PUBMED]
4. Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-beta: the master regulator of fibrosis. Nat Rev Nephrol 2016;12:325-338.
[CROSSREF] [PUBMED] [PDF]
5. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006;17:2999-3012.
[CROSSREF] [PUBMED]
6. Jung GS, Kim MK, Jung YA, Kim HS, Park IS, Min BH, et al. Clusterin attenuates the development of renal fibrosis. J Am Soc Nephrol 2012;23:73-85.
[CROSSREF] [PUBMED]
7. Won JC, Park CY, Oh SW, Lee ES, Youn BS, Kim MS. Plasma clusterin (ApoJ) levels are associated with adiposity and systemic inflammation. PLoS One 2014;9:e103351
[CROSSREF] [PUBMED] [PMC]
8. Derosa G, Maffioli P. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists on glycemic control, lipid profile and cardiovascular risk. Curr Mol Pharmacol 2012;5:272-281.
[CROSSREF] [PUBMED]
9. Cunard R, Ricote M, DiCampli D, Archer DC, Kahn DA, Glass CK, et al. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol 2002;168:2795-2802.
[CROSSREF] [PUBMED]
10. Guan Y, Zhang Y, Breyer MD. The role of PPARs in the transcriptional control of cellular processes. Drug News Perspect 2002;15:147-154.
[CROSSREF] [PUBMED]
11. Smith SA, Lister CA, Toseland CD, Buckingham RE. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes Metab 2000;2:363-372.
[CROSSREF] [PUBMED]
12. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001;59:1899-1910.
[CROSSREF] [PUBMED]
13. Routh RE, Johnson JH, McCarthy KJ. Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. Kidney Int 2002;61:1365-1376.
[CROSSREF] [PUBMED]
14. Guo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, Haneda M. Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. Diabetes 2004;53:200-208.
[CROSSREF] [PUBMED]
15. Kim JW, Kim JR, Yi S, Shin KH, Shin HS, Yoon SH, et al. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-gamma agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects. Clin Ther 2011;33:1819-1830.
[CROSSREF] [PUBMED]
16. Kim SG, Kim DM, Woo JT, Jang HC, Chung CH, Ko KS, et al. Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial. PLoS One 2014;9:e92843
[CROSSREF] [PUBMED] [PMC]
17. Jin SM, Park CY, Cho YM, Ku BJ, Ahn CW, Cha BS, et al. Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension. Diabetes Obes Metab 2015;17:599-602.
[CROSSREF] [PUBMED] [PMC]
18. Lim S, Lee KS, Lee JE, Park HS, Kim KM, Moon JH, et al. Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis. Atherosclerosis 2015;243:107-119.
[CROSSREF] [PUBMED]
19. Jung GS, Jeon JH, Choe MS, Kim SW, Lee IK, Kim MK, et al. Renoprotective effect of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in streptozotocin-induced type 1 diabetic mice. Diabetes Metab J 2016;40:211-221.
[CROSSREF] [PUBMED] [PMC]
20. Jung GS, Kim MK, Choe MS, Lee KM, Kim HS, Park YJ, et al. The orphan nuclear receptor SHP attenuates renal fibrosis. J Am Soc Nephrol 2009;20:2162-2170.
[CROSSREF] [PUBMED] [PMC]
21. Kim H, Haluzik M, Gavrilova O, Yakar S, Portas J, Sun H, et al. Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes. Diabetologia 2004;47:2215-2225.
[CROSSREF] [PUBMED] [PDF]
22. Pistrosch F, Passauer J, Herbrig K, Schwanebeck U, Gross P, Bornstein SR. Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy. Horm Metab Res 2012;44:914-918.
[CROSSREF] [PUBMED] [PDF]
23. Benigni A, Zoja C, Tomasoni S, Campana M, Corna D, Zanchi C, et al. Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. J Am Soc Nephrol 2006;17:1624-1632.
[CROSSREF] [PUBMED]
24. Jesse CR, Bortolatto CF, Wilhelm EA, Roman SS, Prigol M, Nogueira CW. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone protects against cisplatin-induced renal damage in mice. J Appl Toxicol 2014;34:25-32.
[CROSSREF] [PUBMED]
25. Doi S, Masaki T, Arakawa T, Takahashi S, Kawai T, Nakashima A, et al. Protective effects of peroxisome proliferator-activated receptor gamma ligand on apoptosis and hepatocyte growth factor induction in renal ischemia-reperfusion injury. Transplantation 2007;84:207-213.
[CROSSREF] [PUBMED]
26. Lin Q, Gu Y, Ma J, Lin SY. Protection of rosiglitazone against renal interstitial lesion and its mechanism. Zhonghua Yi Xue Za Zhi 2005;85:1618-1624.
[PUBMED]
27. Han JY, Kim YJ, Kim L, Choi SJ, Park IS, Kim JM, et al. PPARgamma agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis. J Korean Med Sci 2010;25:35-41.
[CROSSREF] [PUBMED]
28. Higashi K, Oda T, Kushiyama T, Hyodo T, Yamada M, Suzuki S, et al. Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. Nephrology (Carlton) 2010;15:327-335.
[CROSSREF] [PUBMED]
29. Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T, et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 2009;89:47-58.
[CROSSREF] [PUBMED] [PDF]
30. Lan HY, Chung AC. TGF-beta/Smad signaling in kidney disease. Semin Nephrol 2012;32:236-243.
[CROSSREF] [PUBMED]
31. Meng XM, Huang XR, Chung AC, Qin W, Shao X, Igarashi P, et al. Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. J Am Soc Nephrol 2010;21:1477-1487.
[CROSSREF] [PUBMED] [PMC]
32. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004;18:816-827.
[CROSSREF] [PUBMED]
33. Ohtomo S, Izuhara Y, Takizawa S, Yamada N, Kakuta T, van Ypersele de Strihou C, et al. Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model. Kidney Int 2007;72:1512-1519.
[CROSSREF] [PUBMED]
34. Bae EH, Kim IJ, Ma SK, Kim SW. Rosiglitazone prevents the progression of renal injury in DOCA-salt hypertensive rats. Hypertens Res 2010;33:255-262.
[CROSSREF] [PUBMED] [PDF]